Dementia, GSK and shingles vaccine

This Vaccine Is Now Tied to a 17% Lower Dementia Risk
Getting the Shingrix vaccine after the age of 50 can reduce your chances of developing the painful skin condition known as shingles. Vaccination also might help reduce your risk of dementia, according to a recent study.
GSK studying if best-selling shingles vaccine lowers dementia risk
GSK said on Tuesday that it is studying a group of more than a million older adults in the UK to examine whether its best-selling shingles vaccine lowers the risk of dementia.
GSK partners to trial shingles vaccine in dementia
UK pharma major GSK (LSE: GSK) today announced a major new research collaboration with the UK Dementia Research Institute (UK DRI) and Health Data Research UK (HDR UK) to advance understanding of neurodegeneration with a first-of-its-kind dementia study.
GSK takes advantage of natural experiment to study whether shingles vaccine can reduce dementia risk
After multiple studies have suggested a link between its shingles vaccine and dementia prevention, GSK is taking advantage of a natural experiment to look for more definitive evidence that the shot can reduce dementia risk.
GSK Studying If Blockbuster Shingles Shot Reduces Dementia Risk
GSK Plc is studying a large group of elderly adults in the UK to determine if its blockbuster shingles vaccine reduces the risk of dementia, potentially opening the door to an expanded label for the shot.
UK Pharma Touts Shingles Vaccine To Prevent Dementia
At present, Shingrix is used to prevent herpes zoster (shingles), a painful skin rash caused by the varicella-zoster virus.
Doctors, patients call for widened access to shingles vaccine
Auckland deputy mayor Desley Simpson recently suffered from a painful shingles infection she likened to having "a hedgehog strapped to my face".
STAT10d
Small vaccine maker names Operation Warp Speed leader as chairman, raises $110 million
Moncef Slaoui, who ran the Operation Warp Speed Covid vaccine effort, is becoming chair of Curevo, a company developing a new ...
Shingles vaccine maker Curevo lands $110M, adds biotech vets to board
Curevo, a Seattle-based biotech startup developing a vaccine against shingles, raised $110 million in a Series B ...
The Washington Post12d
Her research grant mentioned ‘hesitancy.’ Now her funding is gone.
Three lab workers are likely to be out of jobs, and research that probed how the shingles vaccine performs in the real world — including benefits and harms — was shut down overnight.
Business Insider10d
Curevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine
during which he helped shape its vaccine business by contributing to the creation of numerous new vaccines including Shingrix ® (shingles), Cervarix ® (HPV-induced cervical cancer), Mosquirix ® ...
Yahoo Finance3d
AIM Vaccine's mRNA Shingles Vaccine Approved by the US FDA to Begin Clinical Trials, AI-Enabled mRNA Major Vaccine Product Development Accelerates
As of now, AIM has obtained FDA approval to begin clinical trials for two major mRNA vaccine products: the mRNA shingles vaccine and the mRNA RSV vaccine. In just one month, AIM has leveraged ...
MedPage Today28d
Shingles Vaccine May Reduce Dementia Risk
Only 45 people need to receive the full shingles vaccination to prevent ... most commercial insurance now fully covering the cost of the vaccine, financial barriers have been significantly ...